Stimulator Implant for Stroke Recovery
Trial Summary
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Research shows that brain-computer interfaces (BCIs) can improve movement in stroke patients by strengthening brain connections, leading to better walking speed and motor function. Additionally, combining BCIs with functional electrical stimulation (FES) has been shown to enhance brain activation and motor control in stroke recovery.
12345There is no specific safety data available for the Stimulator Implant for Stroke Recovery under the names provided. However, a systematic review on non-invasive electrical brain stimulation in stroke patients found that while there is potential for therapeutic benefits, comprehensive evaluation of adverse events is lacking.
25678The Stimulator Implant for Stroke Recovery is unique because it combines a brain-computer interface (BCI) with a neurostimulation device to directly interact with the brain's sensory-motor system, potentially improving motor function after a stroke. This approach is different from traditional therapies as it aims to reintegrate the brain's control over movement, which is not typically addressed by conventional treatments.
910111213Eligibility Criteria
This trial is for stroke survivors aged 21-75 who walk slower than normal due to the stroke. They should be at least 6 months post-stroke, have certain levels of muscle stiffness and motor function, and not need more than one person's help to walk. Participants must also be neurologically stable, speak English, not pregnant, without severe cognitive issues or medical conditions that increase fall risk.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Implantation, Controller Development, and Evaluation
Participants undergo surgery to implant a stimulator and electrodes, followed by training to use the device for walking assistance. Advanced controllers for walking are developed and evaluated over several months.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with evaluations at 18 and 44 weeks post-implant.
Participant Groups
IRS-8 is already approved in United States for the following indications:
- Improving walking in stroke survivors